Victoza (liraglutide 1.8 mg) typically produces modest weight loss in people with type 2 diabetes, but a substantial portion of users see little change on the scale or even gain weight. This is not as contradictory as it sounds. Victoza was approved for blood sugar control, not weight management, and its weight effects are weaker than many people expect. Several biological and practical factors can tip the balance toward weight gain, and understanding which ones apply to you is the first step toward fixing the problem.
Victoza Is Not a Weight-Loss Dose
The single biggest reason people are surprised by weight gain on Victoza is a misunderstanding of what the drug is designed to do. Victoza maxes out at 1.8 mg of liraglutide per day. The same molecule, sold as Saxenda for weight management, goes up to 3.0 mg per day. That nearly 70% higher dose matters enormously for appetite suppression and calorie reduction. In clinical trials, liraglutide 1.8 mg combined with metformin and a sulfonylurea produced an average weight loss of only about 1.4 kg more than placebo over the study period, whereas insulin glargine users in the same trial actually gained weight by comparison, showing a treatment difference of roughly 3.4 kg in favor of liraglutide.1PubMed Central. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial That 1.4 kg advantage over placebo is real, but it is also small enough that everyday fluctuations in water, food timing, or other medications can easily mask it.
If you expected Victoza to produce the kind of dramatic weight loss you have heard about with Ozempic, Wegovy, or Mounjaro, the dose difference is why. A real-world analysis of GLP-1 receptor agonist users found that earlier agents like liraglutide and dulaglutide were “dominated by the minimal weight-loss group,” meaning most users in practice did not achieve the substantial losses seen with newer, more potent drugs.2Biology Methods and Protocols. Decoding the hallmarks of GLP-1RA weight-loss super-responders Victoza still helps many people avoid the weight gain that typically comes with insulin therapy, but “not gaining as much as you would have otherwise” and “losing weight” are different outcomes, and the scale only shows the first if you know what the alternative would have been.
The Hidden Calorie Recapture Effect
Here is one of the less intuitive reasons Victoza can seem to cause weight gain, even though the drug itself promotes modest weight loss. When your blood sugar is poorly controlled, glucose spills into your urine once it exceeds the kidney’s reabsorption threshold. Those are real calories leaving your body, sometimes hundreds per day. You may have been unconsciously eating more to compensate for that calorie loss. Once Victoza brings your blood sugar under better control, that glucose stays in your bloodstream and gets used or stored instead of being flushed away. The calorie leak is plugged, but your appetite may not adjust immediately.3Europe PMC. Weight neutrality with the DPP-4 inhibitor, vildagliptin: mechanistic basis and clinical experience
This effect is not unique to Victoza. Any diabetes medication that effectively lowers blood sugar can reduce glycosuria and remove that calorie escape valve. But it is especially noticeable when someone starts a GLP-1 drug expecting weight loss and instead sees the scale stay flat or creep up. The drug is doing its primary job by controlling glucose. The weight consequence of that improved control can temporarily work against you until your eating habits catch up with your new metabolic reality.
Defensive Eating From Low Blood Sugar Episodes
If Victoza is part of a regimen that also includes a sulfonylurea or insulin, hypoglycemia episodes become more likely. When your blood sugar drops too low, the natural response is to eat, and eat quickly. This “defensive eating” adds calories that would not have been consumed otherwise. Over time, frequent low blood sugar events can train you to snack preemptively, keeping food nearby and eating at the first sign of shakiness or hunger, even if your blood sugar is actually fine.4Europe PMC. Weight neutrality with the DPP-4 inhibitor, vildagliptin: mechanistic basis and clinical experience
Victoza alone carries a low risk of hypoglycemia, but the risk rises sharply when it is combined with insulin or sulfonylureas. If you find yourself treating frequent lows with juice, glucose tabs, or snacks, those extra calories can easily erase whatever small weight-loss benefit Victoza provides. Talking to your prescriber about adjusting the dose of the other medication, rather than assuming Victoza is the problem, is often the more productive fix.
When Combination Therapy Adds Weight
Many people with type 2 diabetes take Victoza alongside other medications, and some of those combinations blunt or reverse the weight effect. A trial studying IDegLira, a fixed-ratio combination of insulin degludec and liraglutide, found that the combination group gained an average of 0.5 kg, while the placebo group lost about 1.0 kg, yielding a treatment difference of roughly 1.5 kg favoring the placebo side.5Diabetic Medicine. Safety and efficacy of insulin degludec/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin‐naïve people with Type 2 diabetes: the DUAL IV trial The insulin component promoted weight gain that the liraglutide component could not fully counteract.
This pattern extends beyond fixed-combination products. If your regimen includes basal insulin, a thiazolidinedione like pioglitazone, or even certain older sulfonylureas, the weight-gaining tendency of those drugs can overwhelm Victoza’s modest weight-loss effect. In such cases, the drug causing the gain is not Victoza itself but another medication in the stack. Your prescriber may be able to swap the offending agent for something more weight-neutral.
Some People Simply Do Not Respond
Individual variation in GLP-1 drug response is significant, and Victoza is no exception. A pooled analysis of liraglutide trials at the higher 3.0 mg dose, not the 1.8 mg Victoza dose, found that about 23% of people without type 2 diabetes were early nonresponders, meaning they did not lose at least 5% of their body weight in the first few months. Among people with type 2 diabetes, that nonresponder rate climbed to about 37%. The nonresponders averaged only around 3% weight loss over a year, compared to roughly 9-11% in early responders.6Obesity. Early Weight Loss with Liraglutide 3.0 mg Predicts 1‐Year Weight Loss and is Associated with Improvements in Clinical Markers
Those numbers are for the 3.0 mg weight-loss dose. At Victoza’s lower 1.8 mg dose, the nonresponder fraction is almost certainly larger. If you have been on Victoza for several months and your weight has not budged or has increased, you may simply be someone whose biology does not respond strongly to liraglutide at this dose. There is no character flaw here. The drug works through specific brain receptors that control appetite, and how strongly those receptors respond varies from person to person for reasons that are still being studied.
Receptor Desensitization Over Time
One emerging explanation for why GLP-1 drugs can lose their punch involves what happens to the receptors they bind to. When a GLP-1 receptor agonist like liraglutide sits on a receptor continuously, the cell gradually pulls that receptor inside, a process called internalization. With fewer receptors available on the cell surface, the same drug dose produces a weaker signal. Newer research into biweekly GLP-1 drugs has shown that building in drug-free intervals allows near-complete receptor recycling back to the surface, preserving the drug’s effectiveness, while continuous exposure drives progressive receptor loss.7Diabetes, Obesity and Metabolism. A Biweekly GLP‐1R Agonist Designed With Drug‐Free Intervals for Enhanced Efficacy, Receptor Homeostasis and Gastrointestinal Tolerability
Liraglutide is injected daily, and its half-life keeps the drug active around the clock. That constant receptor occupancy may partly explain why some users notice strong appetite suppression and weight loss in the first weeks or months, followed by a plateau or gradual weight regain. The receptors are still there, but fewer of them are ready to respond. This area of science is still developing, and no one has proven that receptor desensitization is the primary reason for weight-loss plateaus in humans. But it fits with what many patients describe: the medication felt more powerful at first than it does now.
Your Injection Technique Might Be Off
This one is easy to overlook but surprisingly common. A case series from a diabetes care clinic identified patients whose injectable diabetes medications were not working as expected, and the root cause turned out to be injection errors. In two cases, patients had not removed the inner needle cap, meaning little or no medication was being delivered. In another, switching formulations without proper education led to dosing mistakes. Once the errors were corrected, glycemic control improved markedly in all four patients.8PubMed Central. Patient errors in use of injectable antidiabetic medications: A need for improved clinic-based education
If your Victoza pen is not delivering its full dose because of a technique issue, you are getting less appetite suppression and glucose control than expected. Lipohypertrophy, the buildup of fatty lumps under the skin at repeatedly used injection sites, can also impair drug absorption. Rotating injection sites and having a nurse or pharmacist watch you do an injection at least once are low-effort steps that can rule out this surprisingly frequent problem.
Body Composition Changes the Scale Cannot Show
Weight is a single number that lumps together fat, muscle, water, and everything else. GLP-1 receptor agonists, including liraglutide, tend to reduce fat mass preferentially while relatively preserving lean mass. A review of incretin-based therapies noted that these drugs are generally associated with preferential fat reduction and potential improvement in muscle quality through reduced fat infiltration within the muscle itself.9PubMed Central. Beyond Fat Loss: Addressing the Sarcopenia Challenge of Incretin-Based Therapies A separate analysis using MRI data concluded that the skeletal muscle changes seen with GLP-1 drugs appear to be adaptive, meaning muscle volume changes are proportional to what you would expect given the amount of weight lost, not a sign that the drugs are wasting muscle.10Circulation. Muscle Mass and Glucagon-Like Peptide-1 Receptor Agonists: Adaptive or Maladaptive Response to Weight Loss?
Why does this matter for the scale? If you have started exercising or increased your activity level since beginning Victoza, and the drug is helping you shed some fat while your muscles are being maintained or rebuilt after previous disuse, the net change on the scale can be small or even positive. You may actually be healthier, with less visceral fat and better metabolic markers, even though the number has not dropped. This is not a universal explanation for weight gain on Victoza, but it is a real possibility for people who have also changed their activity habits, and it is worth checking with a waist measurement or body composition test before concluding the drug is failing.
Fluid Shifts and Sodium Handling
GLP-1 receptor agonists affect how your kidneys handle sodium and water. Research shows that GLP-1 receptor activation promotes sodium excretion and decreases sodium reabsorption in the kidney’s proximal tubule, with studies demonstrating roughly a 40% increase in renal sodium clearance during GLP-1 infusion.11Karger Publishers. Addressing Renal Sodium Avidity in Chronic Heart Failure: There Is Always More than One Way to Skin a Cat In theory, this should help reduce fluid retention and lower blood pressure, which it does for most people on these drugs.
But the kidney’s response to any diuretic-like effect is to compensate over time. If you are also eating a high-sodium diet, retaining fluid from other medications like certain blood pressure drugs, or dealing with heart or kidney issues that impair fluid regulation, the net effect on your weight can go either way. A sudden uptick of a couple of pounds over a few days is much more likely to be water than fat, especially if your ankles are swelling or your rings feel tight. This kind of weight gain is usually transient and distinct from the slower fat accumulation that people worry about.
What Changes When You Sleep Differently
An underappreciated side effect of liraglutide is its influence on sleep patterns. Animal research has found that liraglutide dose-dependently decreases wakefulness and increases non-rapid eye movement sleep, with the most pronounced effects occurring during what would normally be the active period.12PubMed Central. Sleep is increased by liraglutide, a glucagon-like peptide-1 receptor agonist, in rats If this translates to humans, and many Victoza users do report increased drowsiness or fatigue, the downstream effects on weight are complex. Better sleep generally supports weight loss, but increased sedation during the day can reduce physical activity and lower your total daily energy expenditure. If you have noticed that Victoza makes you sleepier and you have become less active as a result, that reduced activity could contribute to a caloric surplus over time.
Gut Bacteria Changes and What They Mean
Liraglutide appears to reshape the gut microbiome in ways that are generally favorable for metabolism. In animal studies, liraglutide shifted the balance of gut bacteria, reducing the relative abundance of certain bacterial groups associated with obesity and increasing populations of beneficial microbes like Akkermansia and Lactobacillus.13PubMed Central. Gut microbiota mediates positive effects of liraglutide on dyslipidemia in mice fed a high-fat diet These changes were associated with improvements in cholesterol levels and weight in the study animals.
The relevance to weight gain on Victoza is indirect but worth mentioning. Your gut microbiome is shaped by what you eat, and if your diet has shifted since starting Victoza, perhaps toward more processed or calorie-dense foods because the nausea phase has passed and your appetite has returned, those dietary changes will reshape your gut bacteria in ways that may not support weight loss. The drug can nudge the microbiome in a helpful direction, but it cannot override a diet that consistently provides more calories than your body uses. This is where the behavioral side of the equation becomes just as important as the pharmacological one.
When It Makes Sense to Switch Medications
If you have been on Victoza for several months, your injection technique is correct, your other medications are not working against you, and you are still gaining weight, the honest answer may be that Victoza is not the right tool for your situation. The GLP-1 drug landscape has expanded considerably since liraglutide was first approved. Real-world data show that semaglutide and tirzepatide produce substantially higher rates of clinically meaningful weight loss. In one analysis, Mounjaro (tirzepatide) users had roughly 2.8 times the odds of being a “super responder” compared to Ozempic (semaglutide) users, while earlier agents like liraglutide clustered overwhelmingly in the minimal weight-loss category.14Biology Methods and Protocols. Decoding the hallmarks of GLP-1RA weight-loss super-responders
Switching is not always straightforward. Insurance coverage, cost, availability, and how well Victoza is controlling your blood sugar all factor in. Some people’s diabetes is well managed on Victoza even though the weight effect is disappointing, and swapping to a different medication introduces a new titration period with its own side effects. But if weight management is a priority and Victoza is clearly not delivering, the newer agents represent a genuine step up in potency. Raising this conversation with your prescriber, ideally with a clear timeline of your weight trend and any other symptoms, gives you the best shot at finding something that works on both fronts.
The Nausea Window and What Happens After
Many Victoza users lose the most weight during the first few weeks, when nausea and reduced appetite are strongest. As your body adapts and the gastrointestinal side effects fade, appetite tends to return. This is a predictable part of the drug’s timeline, not a sign that something has gone wrong. But if you ate significantly less during the nausea phase and then returned to your previous eating patterns once you felt better, the weight you initially lost can come back quickly, creating the impression that the drug stopped working or that you are gaining weight “because of” Victoza.
Tracking what and how much you eat during the post-nausea phase, even roughly, can help distinguish between the drug failing and your calorie intake creeping back up. Many clinicians recommend using the appetite-suppressing early weeks as a window to establish new portion sizes and food choices that you can sustain once the nausea wears off. If that window passes without a deliberate dietary shift, the weight trajectory often looks like a brief dip followed by a gradual return to baseline or above.